[A new medication for lung cancer].
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000451:nursing* / Q000523:psychology; D017326:Clinical Trials, Phase III as Topic; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000451:nursing* / Q000523:psychology; D015337:Multicenter Studies as Topic; D010166:Palliative Care; D011788:Quality of Life / Q000523:psychology; D011799:Quinazolines / Q000627:therapeutic use*; D016019:Survival Analysis
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride